Home » Simcere Shuts Down Production in Vaccine Subsidiary Over Quality Control

Simcere Shuts Down Production in Vaccine Subsidiary Over Quality Control

December 4, 2009

Simcere Pharmaceutical Group has stopped a production line at its recently acquired vaccine subsidiary while it reviews quality control systems in the company.
Seeking Alpha

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Simcere Shuts Down Production in Vaccine Subsidiary Over Quality Control

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

Amgen to Buy Five Prime Therapeutics for $1.9 Billion

Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements